Cinclus Pharma Holding (CINPHA) Stock Overview
A clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CINPHA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cinclus Pharma Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 11.98 |
| 52 Week High | SEK 19.64 |
| 52 Week Low | SEK 10.48 |
| Beta | -0.073 |
| 1 Month Change | -0.33% |
| 3 Month Change | -27.13% |
| 1 Year Change | -23.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.26% |
Recent News & Updates
CINPHA: Phase III GERD Readout And Trial Progress Will Support Future Upside
Analysts have maintained their SEK46.25 price target for Cinclus Pharma Holding, citing largely stable assumptions for revenue growth, profit margins and long term P/E expectations. What’s in the News for Cinclus Pharma Holding Cinclus Pharma Holding completed screening of patients in its pivotal Phase III HEEALING1 trial evaluating linaprazan glurate in erosive GERD, with approximately 500 patients enrolled across eight European countries.CINPHA: Phase III GERD Progress Will Drive Future Upside Potential
Analysts now set a price target of SEK46.25 for Cinclus Pharma Holding, down from SEK53.33. This reflects updated assumptions for faster revenue growth of 19.07%, a slightly higher profit margin of 20.05% and a lower future P/E of 108.86x.Recent updates
CINPHA: Phase III GERD Readout And Trial Progress Will Support Future Upside
Analysts have maintained their SEK46.25 price target for Cinclus Pharma Holding, citing largely stable assumptions for revenue growth, profit margins and long term P/E expectations. What’s in the News for Cinclus Pharma Holding Cinclus Pharma Holding completed screening of patients in its pivotal Phase III HEEALING1 trial evaluating linaprazan glurate in erosive GERD, with approximately 500 patients enrolled across eight European countries.CINPHA: Phase III GERD Progress Will Drive Future Upside Potential
Analysts now set a price target of SEK46.25 for Cinclus Pharma Holding, down from SEK53.33. This reflects updated assumptions for faster revenue growth of 19.07%, a slightly higher profit margin of 20.05% and a lower future P/E of 108.86x.CINPHA: FDA Green Light For Single Pivotal Trial Will Drive Upside
Analysts have adjusted their price target on Cinclus Pharma Holding to SEK53.33 from SEK55, reflecting updates to fair value assumptions, growth expectations, margins and a higher projected future P/E multiple. What's in the News The FDA confirms that a single pivotal study supported by additional evidence will be the new standard for US drug approvals, and Cinclus Pharma's current Phase III program for erosive GERD is described as a sufficient basis for a future US regulatory submission (Key Developments).
CINPHA: Upcoming Phase III GERD Results Will Drive Future Upside Potential
Analysts have trimmed their price target on Cinclus Pharma Holding to SEK 40 from SEK 50, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E multiples. What's in the News The FDA clarifies that a single adequate and well controlled pivotal study with supportive evidence will be the new standard for US drug approvals, including for common diseases, and confirms Cinclus Pharma's current Phase III program in erosive GERD as a sufficient basis for a US regulatory submission (company announcement).CINPHA: FDA Guidance Will Support Pivotal Phase III Trial Momentum
Analysts have adjusted their price target for Cinclus Pharma Holding, keeping it at SEK 55.00 per share. Updated forecasts indicate a more cautious outlook for revenue growth, but there is a slight improvement in expected profit margins.CINPHA: Clear FDA Guidance Will Drive Late-Stage Trial Progress
Narrative Update on Cinclus Pharma Holding Analysts have maintained their price target for Cinclus Pharma Holding at SEK 55.00. They noted only minor updates to profit margin and discount rate projections, with no change to their fair value estimate.Advancing Late-Stage GERD Studies Will Drive Substantial Long-Term Upside
Analysts have maintained their price target for Cinclus Pharma Holding at SEK 55.00, citing ongoing expectations for strong profit margins and sustained valuation multiples. What's in the News Cinclus Pharma received positive feedback from the U.S. Food and Drug Administration (FDA) on its Chemistry, Manufacturing, and Controls (CMC) strategy.PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally
Analysts have revised their price target for Cinclus Pharma Holding downwards from SEK 61.67 to SEK 55.00. This change reflects updated views on revenue growth potential and profit margin projections.PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally
Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.Here's Why We're Not Too Worried About Cinclus Pharma Holding's (STO:CINPHA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Cinclus Pharma Holding (STO:CINPHA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Shareholder Returns
| CINPHA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 7.2% | -3.0% | -1.8% |
| 1Y | -23.7% | -23.4% | 10.1% |
Return vs Industry: CINPHA matched the Swedish Pharmaceuticals industry which returned -24.5% over the past year.
Return vs Market: CINPHA underperformed the Swedish Market which returned 8.7% over the past year.
Price Volatility
| CINPHA volatility | |
|---|---|
| CINPHA Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.5% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CINPHA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CINPHA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 17 | Christer Ahlberg | cincluspharma.com |
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori.
Cinclus Pharma Holding AB (publ) Fundamentals Summary
| CINPHA fundamental statistics | |
|---|---|
| Market cap | SEK 557.52m |
| Earnings (TTM) | -SEK 239.07m |
| Revenue (TTM) | SEK 67.51m |
Is CINPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CINPHA income statement (TTM) | |
|---|---|
| Revenue | SEK 67.51m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 67.51m |
| Other Expenses | SEK 306.57m |
| Earnings | -SEK 239.07m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 19, 2026
| Earnings per share (EPS) | -5.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | -354.14% |
| Debt/Equity Ratio | 16.3% |
How did CINPHA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 00:56 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cinclus Pharma Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | DNB Carnegie |
| Fredrik Thor | Redeye |
| Kevin Sule | Redeye |